Abstract:Xiaohui Bian, 1– 3, &ast Jining He, 1– 3, &ast Rui Zhang, 1– 3 Sheng Yuan, 1– 3 Kefei Dou 1– 4 1 Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 3 State Key Laboratory of Cardiovascular Disease, Beijing, People's Republic of China; 4 National Clinical Research Center for Cardiovascular Diseases, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kefei Dou, Cardiometabolic Medicine Center, National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, A 167 Beilishi Road, Xicheng District, Beijing, 100037, People's Republic of China, Tel +86-13801032912, Fax +86-10-6831-3012, Email Background: Chronic low-grade inflammation is the common mechanism of both atherosclerosis and type 2 diabetes mellitus (T2DM), and systemic immune-inflammation index (SII) has been emerged as a novel and simple inflammatory biomarker. However, the association between SII and glycemic metabolism and their synergetic effect on the prognosis of coronary artery disease (CAD) patients remains unclear. Methods: A total of 8602 patients hospitalized for percutaneous coronary intervention (PCI) were included. The primary endpoint was major adverse cardiovascular events (MACE), including all-cause death, myocardial infarction (MI), and target vessel revascularization. According to the optimal cut-off value of SII for MACEs, patients were grouped into higher levels of SII (SII-H) and lower levels of SII (SII-L) and further divided by the concomitance of T2DM into four groups: SII-H/T2DM, SII-H/Non-T2DM, SII-L/T2DM, SII-L/Non-T2DM. Results: During a median 2.4-year follow-up, 522 MACEs occurred. The optimal cut-off value of SII for MACEs was 502.5. A 1-unit increase of SII (transformed by natural logarithm) was associated with a 29% increase of MACE risks in the T2DM cohort [adjusted hazard ratio (HR): 1.29, 95% confidence interval (CI): 1.03 to 1.61, P = 0.024], while had no effect in the non-T2DM cohort (HR: 1.03, 95% CI: 0.80 to 1.34, P = 0.800). Compared to those in SII-H/T2DM group, patients in SII-H/Non-T2DM, SII-L/T2DM, SII-L/Non-T2DM had significantly decreased risk of MACEs [adjusted HR: 0.77, 95% CI: 0.61 to 0.98, P = 0.036; adjusted HR: 0.66, 95% CI: 0.50 to 0.87, P = 0.003; adjusted HR: 0.58, 95% CI: 0.45 to 0.74, P < 0.001; respectively]. Multivariable Cox regression analysis also indicated the highest risk in T2DM patients with higher levels of SII than others (P for trend < 0.001). Conclusion: In this large-scale real-world study, diabetic patients with elevated SII levels were associated with worse clinical outcomes after PCI. Keywords: systemic immune-inflammation index, type 2 diabetes mellitus, coronary artery disease, percutaneous coronary intervention Atherosclerosis is identified as a chronic, low-grade inflammatory condition accompanied by autoimmune responses involving both the innate and adaptive immune systems. 1,2 Numerous observational studies have probed the prognostic value of inflammatory biomarkers in patients with coronary artery disease (CAD), 3,4 and several anti-inflammatory clinical trials have further confirmed the causal relationship between inflammation and CAD. 2 The growth of atherosclerotic lesion is characterized by an imbalance between inflammation and its resolving, with various types of blood cells playing distinct roles in this intricate pathological process. 5 A previous study has indicated that elevated neutrophil-to-lymphocyte ratio (NLR) was associated with adverse prognosis for CAD patients, especially in those with type 2 diabetes mellitus (T2DM). 6 Recent research has also highlighted the involvement of platelets in the recruitment and activation of leukocytes and mediate leukocyte-endothelium adhesion, which play a crucial role in the progression of atherosclerosis. 7,8 The uncontrolled and excessive activation of leukocytes and platelets generates a vicious circle, resulting in plaque instability and vessel occlusion. 9 Therefore, both leukocytes and platelets significantly contribute to the initiation and progression of CAD. -Abstract Truncated-

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Prognostic Impact of Diabetes Mellitus and Index of Microcirculatory Resistance in Patients Undergoing Fractional Flow Reserve-Guided Revascularization

Role of Stromal Cell-Derived Factor-1 in Patients with Non-ST Elevation Acute Coronary Syndrome

Primary Percutaneous Coronary Intervention in Patients With Type 2 Diabetes With Late/Very Late Stent Thrombosis and de novo Lesions: A Single-Center Observational Cohort Study of Clinical Outcomes and Influencing Factors

Predictive Value of Plasma Big Endothelin-1 in Adverse Events of Patients With Coronary Artery Restenosis and Diabetes Mellitus: Beyond Traditional and Angiographic Risk Factors

The Value of Combining Plasma D-Dimer and Endothelin-1 Levels to Predict No-Reflow After Percutaneous Coronary Intervention of ST-Segment Elevation in Acute Myocardial Infarction Patients with a Type 2 Diabetes Mellitus History

The Combined Effect of Systemic Immune-Inflammation Index and Type 2 Diabetes Mellitus on the Prognosis of Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

Correlation Between Plasma Macrophage Migration Inhibitory Factor Levels and Long-Term Prognosis in Patients with Acute Myocardial Infarction Complicated with Diabetes

High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort

Occurrence and predictive risk factors associated with in-stent restenosis after drug-eluting stent implantation in diabetic patients: a prospective, clinical cohort study

Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial

Long-term outcomes after stent implantation in patients with coronary atherosclerotic heart disease and diabetes mellitus

Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

Prognostic Value of Plasma Endothelin-1 in Predicting Worse Outcomes in Patients with Prediabetes and Diabetes and Stable Coronary Artery Diseases

Abstract 12558: 3-year Outcomes In Stable Coronary Artery Disease Patients With Diabetes Based On A Novel Index: Computational Pressure-flow Dynamics Derived Fractional Flow Reserve

Significance of diabetes mellitus status in patients undergoing percutaneous left main coronary artery intervention

Elevated plasma levels of TNF-R1 predict the development of acute ischemic events in coronary patients with diabetes

Diabetic kidney disease as an independent predictor of long-term adverse outcomes in patients with coronary artery disease and diabetic mellitus

Impact of diabetes mellitus on clinical outcomes after first episode in-stent restenosis PCI: Results from a large registry

Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study